Prostate Cancer News on BioPortfolio

Tyme Technologies Taps Eckard for Chief Scientific Affairs Post

Tyme Technologies NASDAQ TYME has appointed Jonathan Eckard chief scientific affairs officer. Eckard most recently worked as chief business and strategy officer for cancer drug developer Sellas Life Sciences. New Yorkbased Tymes lead drug candidate SM88 is...

First HeadtoHead of Chemo for Prostate Cancer

The first headtohead comparison of two chemotherapies for prostate cancer finds similar survival gains but different toxicity profiles. Medscape Medical News

Prostate cancer A new standardofcare for advancedstage disease

Firstline potent androgen blockade for patients with newly diagnosed advancedstage castrationsensitive prostate cancer is confirmed as an effective strategy by data from the STAMPEDE and LATITUDE trials. Herein we highlight the benefits discuss caveats and...

Prostate cancer testing has the bubble burst

In 2010 I wrote a free book on prostate cancer testing with two colleagues Alex Barratt an epidemiologist and Martin Stockler a clinical oncologist Let sleeping dogs lie What men should know before getting tested for prostate cancer. It has been downloaded...